SIRTeX Medical  SIR-Spheres Y90 Resin Microspheres   | Which Medical Device

SIR-Spheres Y90 Resin Microspheres

Added Apr 13, 2013

Manufactured by SIRTeX Medical

Editor Rating

info

User Rating

info
Add your Rating

News/Editorial

SIR-Spheres Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says

Treatment results of Sir-Spheres Y-90 regardless of age
Added Jan 25, 2016 | Posted in News

A new analysis of the MORE data on 606 mCRC patients treated with SIR-Spheres Y-90 resin microspheres at 11 US medical centres, published late last year in Clinical Colorectal Cancer, confirms that patient age is not a barrier to appropriate treatment with the product, Sirtex has reported.

Sirflox Study Abstract released by ASCO
Added May 30, 2015 | Posted in News

Sirtex Medical Limited is pleased to announce that the American Society for Clinical Oncology (ASCO) has published the SIRFLOX Study abstract as part of the 2015 Annual Meeting Abstracts.

Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to \"prolong time to liver tumour progression\" in mCRC patients who have failed to respond to available chemotherapy options.

Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres? Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)

In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver.

In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver.

Sirtex Announces FOXFIRE and FOXFIRE Global Studies
Added Apr 1, 2015 | Posted in News

Sirtex Medical Limited has announced it completed patient enrolment in FOXFIRE and FOXFIRE Global, two large-scale multi-centre clinical trials that combine liver-directed radiation therapy with SIR-Spheres Y-90 resin microspheres to a chemotherapy regimen in over 560 inoperable metastatic colorectal cancer (mCRC) patients.

Sirtex Reports Preliminary SIRFLOX Study Results
Added Apr 1, 2015 | Posted in News

Sirtex Medical Limited (ASX: SRX) is pleased to report the preliminary results of its SIRFLOX clinical study. Based on the preliminary analysis just completed, the primary endpoint of the SIRFLOX study was not achieved. The preliminary analysis shows that adding SIR-Spheres? Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer (mCRC) does not result in a statistically significant improvement in the overall Progression-Free Survival (PFS). Overall PFS measures progression of existing tumours and/or the development of new tumours in any organ or body site.

FOXFIRE UPDATE
Added Mar 26, 2015 | Posted in News

FOXFIRE UPDATE Recruitment to FOXFIRE has now closed. Thank you to all of the sites who contributed in recruiting patients to the trial. The final total was 364; this is a fantastic achievement and will allow the overall survival statistic to be answered.

Similar Devices

  • 1-1
  • of
  • 1
TheraSphere

Manufacturer: BTG

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.